Business
Biomea Fusion Announces Near Doubling the Percentage of Patients with Durable HbA1c Reduction in the 200 mg Dose Cohorts
BMF-219 is an investigational novel covalent menin inhibitor developed to regenerate insulin-producing beta cells with the aim to cure diabetes At Week 26, 22
About this update from Biomea Fusion, Inc.
[{"type":"text","content":"BMF-219 is an investigational novel covalent menin inhibitor developed to regenerate insulin-producing beta cells with the aim to cure diabetes\nAt Week 26, 22 weeks after the last dose of BMF-219, the 200 mg cohorts increased the percentage of patients to approximately 40% with durable HbA1c reduction of 1% or more as compared to the 100 mg cohorts which reported earlier as 20%.To date, the dose escalation portion has shown after only 4 weeks of dosing with BMF-219 that patients across all dosing cohorts have consistently experienced generally meaningful HbA1c reductions and no serious adverse events or study discontinuations. REDWOOD CITY, Calif., Dec. 09, 2023 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea”) (Nasdaq: BMEA), a clinical-stage biopharmaceutical company dedicated to discovering and developing novel covalent small molecules to treat and improve the lives of patients with genetically defined cancers and metabolic diseases, today announced top line data of the 200 mg dose cohorts from the ongoing Phase II clinical study (COVALENT-111) which will be presented in more detail at the International Conference on Advanced Technologies and Treatments of Diabetes (ATTD) in March 2024. “At WCIRDC over the past days, we had the opportunity to lay out the foundational preclinical work and the data sets which supported that beta cell proliferation and their functional improvement is tractable to BMF-219, not only in animals, but also in the human islets, which we studied together with the Harvard Medical School, Joslin Diabetes Center. When inhibiting menin covalently, we observed some of the key signaling pathways and genes that are known to influence beta cell proliferation and function. As presented at the conference, we have shown for the first time the long-term follow-up data of our 100 mg patient cohorts. At ATTD next March, we will further discuss the long-term follow-up data from the 200 mg cohorts,” said Thomas Butler, Biomea Fusion’s Chief Executive Officer and Chairman of the Board. “Today, we can confidently say that we are specifically proliferating beta cells in pancreatic islets. By increasing the dose from 100 mg to 200 mg, we are excited about nearly doubling the percentage of patients treated with BMF-219 having a robust HbA1c reduction of 1% or more, 22 weeks after the last dose. We are now methodically go...